Rheumatoid Arthritis — Common Origins, Divergent Mechanisms | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

The published results of the post-marketing ORAL Surveillance study, which compared the
Janus kinase (JAK) inhibitor tofacitinib with anti-TNF therapy in older patients with …

Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …

Background Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and
are effective disease-modifying treatments for several autoimmune diseases. Whether …

Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …

Summary Background Upadacitinib, a Janus kinase inhibitor, has been shown to be
effective in patients with ankylosing spondylitis. We aimed to assess the efficacy and safety …

Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …

Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib
versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with …

Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …

Background Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis
(RA) but the balance of benefit and harm is still unclear. Methods The GLORIA …